Us Congress 2023-2024 Regular Session

Us Congress Senate Bill SB2141

Introduced
6/22/23  

Caption

Increasing Access to Adviser Information Act

Impact

The legislation requires the SEC to not only extend the no-action determination by an additional 180 days but also to conduct a comprehensive study on the implications of either allowing the determination to expire or maintaining it. The findings are expected to address the availability and competition in the research market, specifically for smaller financial entities. The emphasis on smaller issuers includes a look into the challenges faced by minority-owned, women-owned, or veteran-owned firms, aiming to foster an equitable environment for all market participants.

Summary

SB2141, also known as the Increasing Access to Adviser Information Act, mandates an extension of a no-action determination by the Securities and Exchange Commission (SEC) concerning the provision of research services by broker-dealers. This no-action relief initially granted in 2017 was designed to alleviate compliance issues related to the Markets in Financial Instruments Directive II (MiFID II). The focus of the bill is to explore the compliance burdens placed on investment advisers and ensure that their ability to operate effectively is maintained amidst evolving financial regulations.

Conclusion

In summary, while SB2141 aims to facilitate research and advisory services within the financial sector by allowing broker-dealers to operate under extended no-action relief, it also calls for a critical evaluation of the impacts of such determinations. The bill highlights the delicate balance between regulatory compliance and fostering an equitable market landscape, fostering necessary discourse on how best to serve diverse issuers within the financial market.

Contention

However, the bill has generated discussions regarding the lack of meaningful cost-benefit analysis associated with the no-action relief. Critics argue that previous extensions did not sufficiently account for the repercussions on investors and market participants, potentially undermining transparency and innovative growth within the investment research sector. There are concerns that extending this no-action relief without thorough evaluation may inadvertently benefit larger firms at the expense of smaller entities, leading to an uneven playing field.

Companion Bills

No companion bills found.

Similar Bills

MI HB5187

Individual income tax: economic development; research and development income tax credit program; create. Creates new act. TIE BAR WITH: HB 5100'23, HB 5101'23, HB 5102'23

NJ S3191

Permits certain transportation research contracts to be awarded to private research institutions of higher education and other entities.

CA SB829

California Institute for Scientific Research: CalRx Initiative: vaccines.

CA AB922

Reproductive health and research: oocyte procurement.

VA HB1518

Research and development expenses; tax credits.

VA SB1048

Research and development expenses; tax credits.

VA HB2043

Research and development expenses; increases tax credit.

CA AB1338

Public social services programs: financial assistance demonstration and research programs.